Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sharma, A. M.
Right arrow Articles by Engeli, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, A. M.
Right arrow Articles by Engeli, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 353-355
© 2002 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Managing big issues on lean evidence: treating obesity hypertension

Arya M. Sharma and Stefan Engeli

Franz-Volhard-Klinik, Charité and Max-Delbrück Centre for Molekular Medicine, Berlin-Buch, Germany

Keywords: body weight; hypertension; obesity; therapy; treatment; weight gain

Introduction

Obesity, defined as a body mass index (BMI) greater than 30 kg/m2, is an important risk factor for hypertension, and excess adiposity is believed to account for 70% of hypertension in men and 60% in women [1,2]. There is now accumulating evidence that adipose tissue may itself be involved directly in the pathogenesis of hypertension, not only by contributing to an increase in sympathetic activity [3], but also to sodium and volume retention [4].

Obesity—a risk factor neglected by current guidelines

Current guidelines for the management of hypertension provide specific recommendations for a variety of special patient populations, including patients with diabetes mellitus, coronary . . . [Full Text of this Article]

Antihypertensive treatment of the obese—beyond weight loss

Why specific recommendations for obese hypertensive patients?

Selection of antihypertensive agents in the obese

Conclusion

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
S. Crowley, S. Gurley, M. Oliverio, A. Pazmino, R Griffiths, P. Flannery, R. Spurney, H-S Kim, O Smithies, T. Le, et al.
Is the Kidney Always the Cause of Hypertension?: Distinct Roles for the Kidney and Systemic Tissues in Blood Pressure Regulation by the Renin-Angiotensin System. J Clin Invest 115: 1092-1099, 2005
J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1525 - 1532.
[Full Text] [PDF]

Home page
 HypertensionHome page
A. M. Sharma
Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?
Hypertension, July 1, 2004; 44(1): 12 - 19.
[Abstract] [Full Text] [PDF]